Evidence map›Paper›PMID 40665334›Full record

ArticleBMC medical informatics and decision making2025

An interpretable machine learning model for predicting bone marrow invasion in patients with lymphoma via

Xinyu Zhu, Denglu Lu, Yang Wu, Yanqi Lu, Liang He, Yanyun Deng, Xingyu Mu, Wei Fu

Abstract readMulticenter Study
In one paragraph

Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinyu ZhuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China.
Denglu LuDepartment of Nuclear Medicine, Liuzhou Workers' Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, 545000, China.
Yang WuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China.
Yanqi LuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China.
Liang HeDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China.
Yanyun DengDepartment of Nuclear Medicine, Liuzhou Workers' Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, 545000, China.
Xingyu MuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China. muxingyu1992@hotmail.com.
Wei FuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541001, China. fuwei19700513@163.com.

Funding

National Natural Science Foundation of China 82402332National Natural Science Foundation of China 82460356Natural Science Foundation of Guangxi Zhuang Autonomous Region 2025GXNSFHA069001
6 · The paper itself

Abstract

purposeAccurate identification of bone marrow invasion (BMI) is critical for determining the prognosis of and treatment strategies for lymphoma. Although bone marrow biopsy (BMB) is the current gold standard, its invasive nature and sampling errors highlight the necessity for noninvasive alternatives. We aimed to develop and validate an interpretable machine learning model that integrates clinical data,

methodsWe included 159 newly diagnosed lymphoma patients (118 from Center I and 41 from Center II), excluding those with prior treatments, incomplete data, or under 18 years of age. Data from Center I were randomly allocated to training (n = 94) and internal test (n = 24) sets; Center II served as an external validation set (n = 41). Clinical parameters, PET/CT features, radiomic characteristics, and deep learning features were comprehensively analyzed and integrated into machine learning models. Model interpretability was elucidated via Shapley Additive exPlanations (SHAPs). Additionally, a comparative diagnostic study evaluated reader performance with and without model assistance.

resultsBMI was confirmed in 70 (44%) patients. The key clinical predictors included B symptoms and platelet count. Among the tested models, the ExtraTrees classifier achieved the best performance. For external validation, the combined model (clinical + PET/CT + radiomics + deep learning) achieved an area under the receiver operating characteristic curve (AUC) of 0.886, outperforming models that use only clinical (AUC 0.798), radiomic (AUC 0.708), or deep learning features (AUC 0.662). SHAP analysis revealed that PET radiomic features (especially PET_lbp_3D_m1_glcm_DependenceEntropy), platelet count, and B symptoms were significant predictors of BMI. Model assistance significantly enhanced junior reader performance (AUC improved from 0.663 to 0.818, p = 0.03) and improved senior reader accuracy, although not significantly (AUC 0.768 to 0.867, p = 0.10).

conclusionOur interpretable machine learning model, which integrates clinical, imaging, radiomic, and deep learning features, demonstrated robust BMI prediction performance and notably enhanced physician diagnostic accuracy. These findings underscore the clinical potential of interpretable AI to complement medical expertise and potentially reduce the reliance on invasive BMB for lymphoma staging.

Indexed as

Bone MarrowLymphomaMachine LearningPositron Emission Tomography Computed TomographyAdultAgedDeep LearningFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTBone marrow involvementLymphomaMachine learningRadiomics

Identifiers

PMID40665334
PMCPMC12261613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.